Probiotic Bifidobacterium breve in Improving Cognitive Functions of Older Adults with Suspected Mild Cognitive Impairment: A Randomized, Double-Blind, Placebo-Controlled Trial

Jinzhong Xiao, Noriko Katsumata, Francois Bernier, Kazuya Ohno, Yuki Yamauchi, Toshitaka Odamaki, Kenji Yoshikawa, Kumie Ito, Toshiyuki Kaneko, Jinzhong Xiao, Noriko Katsumata, Francois Bernier, Kazuya Ohno, Yuki Yamauchi, Toshitaka Odamaki, Kenji Yoshikawa, Kumie Ito, Toshiyuki Kaneko

Abstract

Background: Probiotics use has been associated with modulation of inflammation and considered as a possible intervention for CNS diseases such as mild cognitive impairment (MCI) and dementia.

Objective: We aimed to test the effect of the probiotic strain, Bifidobacterium breve A1 (MCC1274), to restore cognition in a physically healthy, suspected MCI population.

Methods: In this randomized, double-blind, placebo-controlled trial, 80 healthy older adults suffering from MCI were divided into two even groups to receive once daily either probiotic (B. breve A1, 2×1010 CFU) or placebo for 16 weeks using a computer-generated algorithm. Cognitive functions were assessed by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) and the Japanese version of the MCI Screen (JMCIS) tests before and after the study as primary and secondary endpoints, respectively.

Results: 79 participants completed the study, and no adverse events were observed. RBANS total score was significantly improved in probiotic group compared with placebo (mean between-group difference 11.3 [95% CI 6.7 to 15.8]; p < 0.0001) after 16 weeks of consumption, in particular with significant improvement in domain scores of immediate memory, visuospatial/constructional, and delayed memory (p < 0.0001), in both intention-to-treat (ITT) analysis and per-protocol (PP) analysis. JMCIS score was also improved versus placebo in ITT analysis (p = 0.052) and PP analysis (p = 0.036).

Conclusion: Study results indicate B. breve A1 is a safe and effective approach for improving memory functions of suspected MCI subjects.

Keywords: Bifidobacterium; clinical trial; dementia; memory; mild cognitive impairment; probiotics.

Conflict of interest statement

Authors’ disclosures are available online (https://www.j-alz.com/manuscript-disclosures/20-0488r1).

Figures

Fig.1
Fig.1
Trial profile.
Fig.2
Fig.2
Changes of RBANS scores at 16 weeks from baseline. Values are indicated as mean with error bars as SE. **p < 0.001, ***p < 0.0001, inter-group difference, Student’s t-test. RBANS, Repeatable Battery for the Assessment of Neuropsychological Status.

References

    1. Morris JC, Storandt M, Miller JP, McKeel DW, Price JL, Rubin EH, Berg L (2001) Mild cognitive impairment represents early-stage Alzheimer disease. Arch Neurol 58, 397–405.
    1. Petersen RC, Caracciolo B, Brayne C, Gauthier S, Jelic V, Fratiglioni L (2014) Mild cognitive impairment: A concept in evolution. J Intern Med 275, 214–228.
    1. Huang LK, Chao SP, Hu CJ (2020) Clinical trials of new drugs for Alzheimer disease. J Biomed Sci 27, 1–13.
    1. Aisen PS (2019) Editorial: Failure after failure. What next in AD drug development? J Prev Alzheimers Dis 6, 150.
    1. Pisa Di, Alonso R, Fernández-Fernández AM, Rábano A, Carrasco L (2017) polymicrobial infections in brain tissue from Alzheimer’s disease patients. Sci Rep 7, 5559.
    1. Fülöp T, Itzhaki RF, Balin BJ, Miklossy J, Barron AE (2018) Role of microbes in the development of Alzheimer’s disease: State of the Art - An International Symposium Presented at the 2017 IAGG Congress in San Francisco. Front Genet 9, 362.
    1. Adan RAH, van der Beek EM, Buitelaar JK, Cryan JF, Hebebrand J, Higgs S, Schellekens H, Dickson SL (2019) Nutritional psychiatry: Towards improving mental health by what you eat. Neuropsychopharmacol 29, 1321–1332.
    1. Iuliano E, Di Cagno A, Cristofano A, Angiolillo A, D’Aversa R, Ciccotelli S, Corbi G, Fiorilli G, Calcagno G, Di Costanzo A, Aquino G, Arcari V, Buongusto L, Cavallo G, Faraone M, Ferrara N, Filangieri M, Fiscarelli M, Iavarone S, Iannetta F, Moffa S, Mignogna P, Oriani G, Palombo F, Panichella T, Pedata S, Petti B, Spaziano M, Taglialatela M, Valente R (2019) Physical exercise for prevention of dementia (EPD) study: Background, design and methods. BMC Public Health 19, 659.
    1. Wang X, Sun G, Feng T, Zhang J, Huang X, Wang T, Xie Z, Chu X, Yang J, Wang H, Chang S, Gong Y, Ruan L, Zhang G, Yan S, Lian W, Du C, Yang D, Zhang Q, Lin F, Liu J, Zhang H, Ge C, Xiao S, Ding J, Geng M (2019) Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer’s disease progression. Cell Res 29, 787–803.
    1. Fortier M, Castellano CA, Croteau E, Langlois F, Bocti C, St-Pierre V, Vandenberghe C, Bernier M, Roy M, Descoteaux M, Whittingstall K, Lepage M, Turcotte ÉE, Fulop T, Cunnane SC (2019) A ketogenic drink improves brain energy and some measures of cognition in mild cognitive impairment. Alzheimers Dement 15, 625–634.
    1. Joint FAO/WHO Working group. Guidelines for the evaluation of probiotics in food. . Last update 2002.
    1. Cryan JF, O’riordan KJ, Cowan CSM, John F. Sandhu KV, Bastiaanssen TFS, Boehme M, Codagnone MG, Cussotto S, Fulling C, Golubeva AV, Guzzetta KE, Jaggar M, Long-Smith CM, Lyte JM, Martin JA, Molinero-Perez A, Moloney G, Morelli VE, Morillas E, O’Connor R, Cruz-Pereira JS, Peterson VL, Rea K, Ritz NL, Sherwin E, Spichak S, Teichman EM, van de Wouw M, Ventura-Silva AP, Wallace-Fitzsimons SE, Hyland N, Clarke G, Dinan TG (2019) The microbiota-gut-brain axis. Physiol Rev 99, 1877–2013.
    1. Wraith DC, Nicholson LB, Wraith DC, Nicholson LB (2012) The adaptive immune system in diseases of the central nervous system Find the latest version: Review series The adaptive immune system in diseases of the central nervous system. J Clin Invest 122, 1172–1179.
    1. Kobayashi Y, Sugahara H, Shimada K, Mitsuyama E, Kuhara T, Yasuoka A, Kondo T, Abe K, Xiao JZ (2017) Therapeutic potential of Bifidobacterium breve strain A1 for preventing cognitive impairment in Alzheimer’s disease. Sci Rep 7, 13510.
    1. Kobayashi Y, Kuhara T, Oki M, Xiao JZ (2019) Effects of Bifidobacterium breve A1 on the cognitive function of older adults with memory complaints: A randomised, double-blind, placebo-controlled trial. Benef Microbes 10, 511–520.
    1. Cho A, Sugimura M, Nakano S, Yamada T (2008) Current topics in management: The Japanese MCI Screen for early detection of Alzheimer’s disease and related disorders. Am J Alzheimers Dis Other Demen 23, 162–166.
    1. Karantzoulis S, Novitski J, Gold M, Randolph C (2013) The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): Utility in detection and characterization of mild cognitive impairment due to Alzheimer’s disease. Arch Clin Neuropsychol 28, 837–844.
    1. Kotani S, Sakaguchi E, Warashina S, Matsukawa N, Ishikura Y, Kiso Y, Sakakibara M, Yoshimoto T, Guo J, Yamashima T (2006) Dietary supplementation of arachidonic and docosahexaenoic acids improves cognitive dysfunction. Neurosci Res 56, 159–164.
    1. Ohsawa K, Nakamura F, Uchida N, Mizuno S, Yokogoshi H (2018) Lactobacillus helveticus-fermented milk containing lactononadecapeptide (NIPPLTQTPVVVPPFLQPE) improves cognitive function in healthy middle-aged adults: A randomised, double-blind, placebo-controlled trial. Int J Food Sci Nutr 69, 369–376.
    1. Suzanne M, Norbert S, Kristine Y, Catherine M, Bruce M, Weiner MW (2010) Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer’s disease. Hum Brain Mapp 31, 1339–1347.
    1. England HB, Gillis MM, Hampstead BM (2014) RBANS memory indices are related to medial temporal lobe volumetrics in healthy older adults and those with mild cognitive impairment. Arch Clin Neuropsychol 29, 322–328.
    1. Lee HJ, Lee KE, Kim JK, Kim DH (2019) Suppression of gut dysbiosis by Bifidobacterium longum alleviates cognitive decline in 5XFAD transgenic and aged mice. Sci Rep 9, 11814.
    1. Knezevic D, Mizrahi R (2018) Molecular imaging of neuroinflammation in Alzheimer’s disease and mild cognitive impairment. Prog Neuropsychopharmacol Biol Psychiatry 80 (Pt B), 123–131.
    1. Ruiz L, Delgado S, Ruas-Madiedo P, Sánchez B, Margolles A (2017) Bifidobacteria and their molecular communication with the immune system. Front Microbiol 8, 345.
    1. Alagón Fernández del Campo P, De Orta Pando A, Straface JI, López Vega JR, Toledo Plata D, Niezen Lugo SF, Alvarez Hernández D, Barrientos Fortes T, Gutiérrez–Kobeh L, Solano-Gálvez SG, Vázquez-López R (2019) The use of probiotic therapy to modulate the gut microbiota and dendritic cell responses in inflammatory bowel diseases. Med Sci (Basel) 7, 33.
    1. Sakurai T, Odamaki T, Xiao JZ (2019) Production of indole-3-lactic acid by Bifidobacterium strains isolated from human infants. Microorganisms 7, 340.
    1. Wang CB, Tanaka A, Kuhara T, Xiao JZ (2020) Potential effects of indole-3-lactic acid, a metabolite of human bifidobacteria, on NGF- induced neurite outgrowth in PC12 cells. Microorganisms 8, 398.
    1. Meng D, Sommella E, Salviati E, Campiglia P, Ganguli K, Djebali K, Zhu W, Walker AW (2020) Indole-3-lactic acid, a metabolite of tryptophan, secreted by Bifidobacterium longum subspecies infantis is anti-inflammatory in the immature intestine. Pediatr Res, doi: 10.1038/s41390-019-0740-x.
    1. Jang HM, Lee KE, Kim DH (2019) The preventive and curative effects of Lactobacillus reuteri NK33 and Bifidobacterium adolescentis NK98 on immobilization stress-induced anxiety/depression and colitis in mice. Nutrients 11, 819.
    1. Lima Giacobbo B, Doorduin J, Klein HC, Dierckx RAJO, Bromberg E, de Vries EFJ (2019) Brain-derived neurotrophic factor in brain disorders: Focus on neuroinflammation. Mol Neurobiol 56, 3295–3312.
    1. Angelucci F, Spalletta G, Iulio F, Ciaramella A, Salani F, Varsi A, Gianni W, Sancesario G, Caltagirone C, Bossu P (2010) Alzheimer’s disease (AD) and mild cognitive impairment (MCI) patients are characterized by increased BDNF serum levels. Curr Alzheimer Res 7, 15–20.
    1. Dodiya HB, Kuntz T, Shaik SM, Baufeld C, Leibowitz J, Zhang X, Gottel N, Zhang X, Butovsky O, Gilbert JA, Sisodia SS (2019) Sex-specific effects of microbiome perturbations on cerebral Ab amyloidosis and microglia phenotypes. J Exp Med 216, 1542–1560.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe